Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Frail Elderly | 65 | 2025 | 774 | 11.800 |
Why?
|
Geriatric Assessment | 53 | 2024 | 1422 | 9.410 |
Why?
|
Medicare | 68 | 2025 | 6881 | 4.530 |
Why?
|
Dementia | 21 | 2024 | 2723 | 3.750 |
Why?
|
Activities of Daily Living | 25 | 2024 | 2433 | 3.400 |
Why?
|
Independent Living | 18 | 2024 | 580 | 3.310 |
Why?
|
Aged | 202 | 2025 | 171520 | 2.390 |
Why?
|
Skilled Nursing Facilities | 6 | 2023 | 406 | 2.050 |
Why?
|
Insurance Claim Review | 8 | 2024 | 745 | 1.970 |
Why?
|
Heart Valve Prosthesis Implantation | 9 | 2021 | 1569 | 1.790 |
Why?
|
Delirium | 8 | 2024 | 1694 | 1.790 |
Why?
|
Aortic Valve Stenosis | 16 | 2024 | 2032 | 1.780 |
Why?
|
Sarcopenia | 6 | 2024 | 376 | 1.750 |
Why?
|
Antipsychotic Agents | 7 | 2023 | 3077 | 1.740 |
Why?
|
Pneumonia | 5 | 2022 | 2162 | 1.710 |
Why?
|
Aged, 80 and over | 89 | 2025 | 59680 | 1.680 |
Why?
|
Atrial Fibrillation | 14 | 2024 | 5162 | 1.640 |
Why?
|
Hypertension | 17 | 2023 | 8611 | 1.610 |
Why?
|
Cardiovascular Diseases | 21 | 2024 | 15638 | 1.510 |
Why?
|
Republic of Korea | 12 | 2023 | 587 | 1.510 |
Why?
|
United States | 96 | 2025 | 73121 | 1.480 |
Why?
|
Cholinesterase Inhibitors | 3 | 2024 | 242 | 1.320 |
Why?
|
Humans | 260 | 2025 | 768451 | 1.260 |
Why?
|
Antihypertensive Agents | 12 | 2023 | 2028 | 1.250 |
Why?
|
Memantine | 2 | 2024 | 111 | 1.230 |
Why?
|
Patient Discharge | 10 | 2024 | 3471 | 1.220 |
Why?
|
Aortic Valve | 11 | 2021 | 1968 | 1.210 |
Why?
|
Blood Pressure | 16 | 2023 | 8538 | 1.190 |
Why?
|
Blood Pressure Determination | 6 | 2023 | 646 | 1.150 |
Why?
|
Heart Valve Prosthesis | 4 | 2020 | 1468 | 1.130 |
Why?
|
Male | 137 | 2024 | 364781 | 1.130 |
Why?
|
Patient Readmission | 7 | 2024 | 3308 | 1.110 |
Why?
|
Female | 142 | 2025 | 396943 | 1.100 |
Why?
|
Pharmacoepidemiology | 2 | 2024 | 352 | 1.070 |
Why?
|
Anticoagulants | 11 | 2024 | 4840 | 1.070 |
Why?
|
Myocardial Infarction | 11 | 2024 | 11515 | 1.040 |
Why?
|
Erectile Dysfunction | 2 | 2020 | 445 | 1.000 |
Why?
|
Nursing Homes | 8 | 2024 | 1084 | 0.950 |
Why?
|
Warfarin | 7 | 2024 | 1493 | 0.950 |
Why?
|
Health Status Indicators | 2 | 2020 | 971 | 0.920 |
Why?
|
Dipeptidyl-Peptidase IV Inhibitors | 4 | 2023 | 317 | 0.880 |
Why?
|
Heart Failure | 11 | 2023 | 11857 | 0.880 |
Why?
|
Disability Evaluation | 5 | 2016 | 1839 | 0.880 |
Why?
|
Platelet Aggregation Inhibitors | 5 | 2024 | 2768 | 0.870 |
Why?
|
Recovery of Function | 5 | 2021 | 2994 | 0.870 |
Why?
|
Retrospective Studies | 54 | 2024 | 81834 | 0.860 |
Why?
|
International Classification of Diseases | 4 | 2021 | 925 | 0.840 |
Why?
|
Disabled Persons | 5 | 2019 | 1218 | 0.810 |
Why?
|
Propensity Score | 8 | 2024 | 1971 | 0.810 |
Why?
|
Subacute Care | 2 | 2023 | 188 | 0.790 |
Why?
|
Decision Support Techniques | 2 | 2022 | 2010 | 0.770 |
Why?
|
Fee-for-Service Plans | 2 | 2024 | 714 | 0.760 |
Why?
|
Postoperative Complications | 10 | 2024 | 15880 | 0.750 |
Why?
|
Sulfonylurea Compounds | 3 | 2023 | 220 | 0.730 |
Why?
|
Diabetes Mellitus, Type 2 | 12 | 2024 | 12242 | 0.720 |
Why?
|
Risk Factors | 48 | 2024 | 74915 | 0.720 |
Why?
|
Hospital Mortality | 8 | 2024 | 5371 | 0.720 |
Why?
|
Cardiac Surgical Procedures | 5 | 2023 | 3682 | 0.720 |
Why?
|
Coronary Artery Disease | 7 | 2023 | 6551 | 0.700 |
Why?
|
Risk Assessment | 24 | 2024 | 24311 | 0.700 |
Why?
|
Long-Term Care | 1 | 2024 | 633 | 0.700 |
Why?
|
Randomized Controlled Trials as Topic | 13 | 2024 | 10358 | 0.670 |
Why?
|
Hospital Records | 1 | 2019 | 93 | 0.670 |
Why?
|
Hearing Aids | 1 | 2020 | 58 | 0.660 |
Why?
|
Prospective Studies | 32 | 2024 | 54914 | 0.650 |
Why?
|
Vascular Malformations | 2 | 2015 | 469 | 0.650 |
Why?
|
Medicare Part C | 1 | 2024 | 332 | 0.640 |
Why?
|
Dexmedetomidine | 1 | 2023 | 320 | 0.640 |
Why?
|
Fractures, Bone | 5 | 2023 | 2063 | 0.630 |
Why?
|
Survival Rate | 11 | 2022 | 12875 | 0.630 |
Why?
|
Coronary Artery Bypass | 5 | 2023 | 2194 | 0.630 |
Why?
|
Cognition Disorders | 6 | 2016 | 3985 | 0.630 |
Why?
|
Pemphigoid, Bullous | 1 | 2020 | 113 | 0.630 |
Why?
|
Ventricular Dysfunction, Left | 3 | 2023 | 2145 | 0.630 |
Why?
|
Aging | 8 | 2023 | 8761 | 0.620 |
Why?
|
Cohort Studies | 22 | 2024 | 41797 | 0.590 |
Why?
|
Ischemic Attack, Transient | 1 | 2023 | 878 | 0.590 |
Why?
|
Community-Acquired Infections | 1 | 2021 | 473 | 0.570 |
Why?
|
Quality of Life | 11 | 2023 | 13497 | 0.570 |
Why?
|
Patient-Centered Care | 2 | 2018 | 1439 | 0.560 |
Why?
|
Renal Insufficiency, Chronic | 4 | 2023 | 2291 | 0.550 |
Why?
|
Accidental Falls | 6 | 2023 | 1081 | 0.550 |
Why?
|
Pravastatin | 1 | 2018 | 393 | 0.540 |
Why?
|
Phenotype | 9 | 2024 | 16712 | 0.520 |
Why?
|
Veterans | 7 | 2023 | 2671 | 0.520 |
Why?
|
Haloperidol | 3 | 2023 | 394 | 0.520 |
Why?
|
Treatment Outcome | 36 | 2024 | 65409 | 0.500 |
Why?
|
Rural Population | 5 | 2022 | 2317 | 0.500 |
Why?
|
Surgical Procedures, Operative | 3 | 2024 | 1937 | 0.490 |
Why?
|
Retinal Diseases | 2 | 2011 | 711 | 0.490 |
Why?
|
Health Status | 3 | 2018 | 4096 | 0.480 |
Why?
|
Thoracic Surgical Procedures | 1 | 2018 | 350 | 0.460 |
Why?
|
Ticlopidine | 2 | 2009 | 730 | 0.460 |
Why?
|
Polypharmacy | 3 | 2022 | 307 | 0.450 |
Why?
|
Cross-Sectional Studies | 17 | 2024 | 26351 | 0.450 |
Why?
|
Vulnerable Populations | 2 | 2020 | 717 | 0.450 |
Why?
|
Diphosphonates | 2 | 2016 | 635 | 0.440 |
Why?
|
Mortality | 6 | 2021 | 2917 | 0.440 |
Why?
|
Nutritional Status | 3 | 2018 | 1623 | 0.440 |
Why?
|
Aspirin | 2 | 2019 | 3139 | 0.430 |
Why?
|
Patient Admission | 1 | 2021 | 1370 | 0.430 |
Why?
|
Acute Kidney Injury | 3 | 2024 | 1943 | 0.430 |
Why?
|
Stroke | 8 | 2024 | 9791 | 0.430 |
Why?
|
Syncope | 2 | 2018 | 430 | 0.430 |
Why?
|
Comorbidity | 10 | 2024 | 10601 | 0.420 |
Why?
|
Hip Fractures | 4 | 2024 | 996 | 0.420 |
Why?
|
Administration, Oral | 5 | 2024 | 4041 | 0.420 |
Why?
|
Adrenergic beta-Antagonists | 5 | 2023 | 1244 | 0.420 |
Why?
|
Social Behavior | 1 | 2019 | 1144 | 0.410 |
Why?
|
Bone Density Conservation Agents | 2 | 2022 | 797 | 0.410 |
Why?
|
Drug Prescriptions | 2 | 2020 | 1677 | 0.410 |
Why?
|
Hearing Loss | 1 | 2020 | 786 | 0.410 |
Why?
|
Prognosis | 14 | 2025 | 30028 | 0.400 |
Why?
|
Cognition | 7 | 2021 | 7066 | 0.400 |
Why?
|
Interpersonal Relations | 1 | 2019 | 1439 | 0.390 |
Why?
|
Geriatrics | 1 | 2016 | 390 | 0.390 |
Why?
|
Severity of Illness Index | 11 | 2024 | 15965 | 0.390 |
Why?
|
Life Expectancy | 2 | 2019 | 1249 | 0.380 |
Why?
|
Cause of Death | 3 | 2021 | 3727 | 0.370 |
Why?
|
Anticholesteremic Agents | 1 | 2018 | 972 | 0.370 |
Why?
|
Hemorrhage | 6 | 2024 | 3458 | 0.370 |
Why?
|
Drug Utilization | 1 | 2017 | 1192 | 0.370 |
Why?
|
Primary Prevention | 1 | 2018 | 1189 | 0.360 |
Why?
|
Kaplan-Meier Estimate | 6 | 2020 | 6537 | 0.360 |
Why?
|
Prevalence | 12 | 2023 | 15880 | 0.360 |
Why?
|
Dopamine Agents | 1 | 2011 | 190 | 0.350 |
Why?
|
France | 6 | 2024 | 497 | 0.350 |
Why?
|
Nootropic Agents | 1 | 2011 | 159 | 0.340 |
Why?
|
Exercise | 4 | 2020 | 5940 | 0.340 |
Why?
|
Checklist | 1 | 2017 | 843 | 0.340 |
Why?
|
Seafood | 1 | 2013 | 395 | 0.340 |
Why?
|
Hospitalization | 12 | 2023 | 10845 | 0.340 |
Why?
|
Health Status Disparities | 3 | 2019 | 1876 | 0.330 |
Why?
|
Coronary Artery Bypass, Off-Pump | 1 | 2009 | 65 | 0.330 |
Why?
|
Benzethonium | 1 | 2009 | 6 | 0.330 |
Why?
|
Paromomycin | 1 | 2009 | 14 | 0.330 |
Why?
|
Respiratory Insufficiency | 1 | 2018 | 1244 | 0.330 |
Why?
|
Electronic Health Records | 2 | 2024 | 4877 | 0.330 |
Why?
|
Time Factors | 15 | 2025 | 40271 | 0.330 |
Why?
|
Hand Strength | 3 | 2021 | 465 | 0.320 |
Why?
|
Pyridones | 3 | 2024 | 819 | 0.320 |
Why?
|
Data Interpretation, Statistical | 6 | 2020 | 2705 | 0.310 |
Why?
|
Patient Acceptance of Health Care | 4 | 2024 | 3237 | 0.310 |
Why?
|
Drug-Eluting Stents | 2 | 2019 | 681 | 0.310 |
Why?
|
Age Factors | 11 | 2021 | 18478 | 0.310 |
Why?
|
Antiprotozoal Agents | 1 | 2009 | 95 | 0.310 |
Why?
|
Pyrazoles | 3 | 2024 | 2024 | 0.310 |
Why?
|
Diabetes Mellitus | 2 | 2023 | 5887 | 0.290 |
Why?
|
Incidence | 9 | 2021 | 21552 | 0.290 |
Why?
|
Depression | 4 | 2023 | 8235 | 0.290 |
Why?
|
Leishmaniasis, Cutaneous | 1 | 2009 | 137 | 0.280 |
Why?
|
Adiponectin | 1 | 2013 | 1118 | 0.280 |
Why?
|
HIV Infections | 3 | 2022 | 17564 | 0.280 |
Why?
|
Health Services for the Aged | 1 | 2009 | 258 | 0.280 |
Why?
|
Algorithms | 5 | 2024 | 14158 | 0.270 |
Why?
|
Cardiology Service, Hospital | 1 | 2008 | 241 | 0.270 |
Why?
|
Comparative Effectiveness Research | 2 | 2023 | 712 | 0.260 |
Why?
|
Cardiac Output, Low | 1 | 2007 | 191 | 0.260 |
Why?
|
Canada | 6 | 2024 | 2143 | 0.260 |
Why?
|
Carotid Artery Diseases | 2 | 2011 | 879 | 0.260 |
Why?
|
Clinical Trials as Topic | 2 | 2021 | 8051 | 0.250 |
Why?
|
Hypoglycemic Agents | 7 | 2024 | 3111 | 0.250 |
Why?
|
Self Report | 3 | 2022 | 3771 | 0.250 |
Why?
|
Stroke Volume | 6 | 2023 | 5620 | 0.240 |
Why?
|
Odds Ratio | 7 | 2022 | 9687 | 0.240 |
Why?
|
Retinal Vessels | 1 | 2011 | 864 | 0.240 |
Why?
|
Forecasting | 1 | 2014 | 2950 | 0.240 |
Why?
|
Institutionalization | 2 | 2023 | 108 | 0.240 |
Why?
|
Carbonated Beverages | 1 | 2006 | 210 | 0.240 |
Why?
|
Biomedical Research | 2 | 2020 | 3463 | 0.240 |
Why?
|
Terminal Care | 3 | 2021 | 1773 | 0.240 |
Why?
|
Preventive Health Services | 1 | 2009 | 568 | 0.240 |
Why?
|
Shock, Septic | 1 | 2011 | 774 | 0.230 |
Why?
|
Morbidity | 4 | 2023 | 1760 | 0.230 |
Why?
|
Dietary Fats | 2 | 2012 | 2003 | 0.220 |
Why?
|
Coronary Disease | 1 | 2018 | 5926 | 0.220 |
Why?
|
Length of Stay | 4 | 2024 | 6521 | 0.220 |
Why?
|
Central Nervous System Agents | 1 | 2024 | 74 | 0.220 |
Why?
|
Middle Aged | 27 | 2024 | 223418 | 0.220 |
Why?
|
Hypotension | 1 | 2009 | 888 | 0.220 |
Why?
|
Breast Neoplasms | 5 | 2025 | 21156 | 0.220 |
Why?
|
Acute Coronary Syndrome | 2 | 2024 | 2195 | 0.220 |
Why?
|
Microcirculation | 3 | 2014 | 1282 | 0.210 |
Why?
|
Peripheral Vascular Diseases | 1 | 2006 | 489 | 0.210 |
Why?
|
Receptors, Angiotensin | 1 | 2023 | 141 | 0.210 |
Why?
|
Survival Analysis | 7 | 2021 | 10125 | 0.210 |
Why?
|
Cerebrovascular Disorders | 1 | 2010 | 1487 | 0.210 |
Why?
|
Advance Care Planning | 2 | 2020 | 698 | 0.210 |
Why?
|
Heart Rate | 3 | 2019 | 4218 | 0.200 |
Why?
|
Databases, Factual | 7 | 2024 | 8081 | 0.200 |
Why?
|
Life Style | 3 | 2024 | 3929 | 0.200 |
Why?
|
Glaucoma | 2 | 2023 | 1193 | 0.200 |
Why?
|
Proportional Hazards Models | 8 | 2022 | 12561 | 0.200 |
Why?
|
Cholesterol, HDL | 2 | 2009 | 1820 | 0.200 |
Why?
|
Models, Statistical | 2 | 2014 | 5103 | 0.190 |
Why?
|
Vitamin K | 1 | 2024 | 314 | 0.190 |
Why?
|
Melanosis | 1 | 2022 | 93 | 0.190 |
Why?
|
Coffee | 1 | 2006 | 598 | 0.190 |
Why?
|
Caffeine | 1 | 2006 | 702 | 0.190 |
Why?
|
Dietary Supplements | 2 | 2018 | 3445 | 0.190 |
Why?
|
Risperidone | 1 | 2023 | 383 | 0.180 |
Why?
|
Colorectal Surgery | 1 | 2023 | 122 | 0.180 |
Why?
|
Demography | 2 | 2016 | 1643 | 0.180 |
Why?
|
Purinergic P2Y Receptor Antagonists | 1 | 2023 | 284 | 0.180 |
Why?
|
Drug Therapy | 1 | 2024 | 504 | 0.180 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2015 | 3253 | 0.170 |
Why?
|
Neprilysin | 1 | 2023 | 487 | 0.170 |
Why?
|
Withholding Treatment | 1 | 2024 | 621 | 0.170 |
Why?
|
Health Care Costs | 2 | 2023 | 3265 | 0.170 |
Why?
|
Oxadiazoles | 1 | 2020 | 94 | 0.170 |
Why?
|
Medical Oncology | 3 | 2022 | 2347 | 0.170 |
Why?
|
Predictive Value of Tests | 6 | 2021 | 15460 | 0.170 |
Why?
|
Embolism | 1 | 2023 | 401 | 0.170 |
Why?
|
Depressive Disorder | 2 | 2011 | 3738 | 0.170 |
Why?
|
Stomach Neoplasms | 2 | 2021 | 1484 | 0.170 |
Why?
|
Aromatase | 1 | 2020 | 147 | 0.170 |
Why?
|
Alzheimer Disease | 3 | 2023 | 8721 | 0.170 |
Why?
|
Preoperative Care | 2 | 2019 | 2257 | 0.170 |
Why?
|
Hypoglycemia | 2 | 2024 | 894 | 0.170 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 3 | 2023 | 11843 | 0.170 |
Why?
|
Decision Making | 3 | 2018 | 3961 | 0.170 |
Why?
|
Osteoporosis | 2 | 2022 | 1606 | 0.170 |
Why?
|
SEER Program | 1 | 2025 | 1476 | 0.160 |
Why?
|
Hospitals | 2 | 2023 | 3906 | 0.160 |
Why?
|
Consensus | 2 | 2019 | 3207 | 0.160 |
Why?
|
Current Procedural Terminology | 1 | 2020 | 101 | 0.160 |
Why?
|
Exercise Therapy | 1 | 2006 | 941 | 0.160 |
Why?
|
Telephone | 1 | 2022 | 630 | 0.160 |
Why?
|
Atrial Appendage | 1 | 2023 | 285 | 0.160 |
Why?
|
Iceland | 1 | 2019 | 184 | 0.160 |
Why?
|
Trifluridine | 1 | 2019 | 28 | 0.160 |
Why?
|
Research Design | 4 | 2022 | 6217 | 0.160 |
Why?
|
Longitudinal Studies | 6 | 2024 | 14766 | 0.160 |
Why?
|
Risk | 4 | 2015 | 9642 | 0.160 |
Why?
|
Vitamin D Deficiency | 1 | 2008 | 1389 | 0.160 |
Why?
|
Walking | 1 | 2006 | 1202 | 0.160 |
Why?
|
Stents | 2 | 2019 | 3204 | 0.150 |
Why?
|
Accidents, Home | 1 | 2018 | 73 | 0.150 |
Why?
|
Habits | 1 | 2019 | 147 | 0.150 |
Why?
|
Inappropriate Prescribing | 1 | 2021 | 212 | 0.150 |
Why?
|
Cholesterol, LDL | 1 | 2007 | 2396 | 0.150 |
Why?
|
Health Behavior | 1 | 2009 | 2649 | 0.150 |
Why?
|
Wet Macular Degeneration | 1 | 2020 | 165 | 0.150 |
Why?
|
Psychotropic Drugs | 1 | 2023 | 888 | 0.150 |
Why?
|
Propanolamines | 1 | 2018 | 164 | 0.140 |
Why?
|
Osteoporotic Fractures | 1 | 2022 | 417 | 0.140 |
Why?
|
Water-Electrolyte Imbalance | 1 | 2018 | 110 | 0.140 |
Why?
|
Chemotherapy, Adjuvant | 3 | 2024 | 3550 | 0.140 |
Why?
|
Benzodiazepines | 1 | 2023 | 1139 | 0.140 |
Why?
|
Critical Care | 2 | 2020 | 2717 | 0.140 |
Why?
|
Muscular Dystrophy, Duchenne | 1 | 2020 | 271 | 0.140 |
Why?
|
Sex Factors | 3 | 2020 | 10647 | 0.140 |
Why?
|
Logistic Models | 5 | 2020 | 13324 | 0.140 |
Why?
|
Task Performance and Analysis | 1 | 2020 | 771 | 0.140 |
Why?
|
Confidence Intervals | 3 | 2020 | 2932 | 0.140 |
Why?
|
Stress, Physiological | 1 | 2024 | 1409 | 0.140 |
Why?
|
Random Allocation | 1 | 2021 | 2399 | 0.130 |
Why?
|
Angiotensin Receptor Antagonists | 1 | 2023 | 1066 | 0.130 |
Why?
|
Postoperative Hemorrhage | 1 | 2020 | 420 | 0.130 |
Why?
|
Systole | 2 | 2009 | 938 | 0.130 |
Why?
|
Residence Characteristics | 3 | 2022 | 2119 | 0.130 |
Why?
|
Hypnotics and Sedatives | 1 | 2023 | 1188 | 0.120 |
Why?
|
Evidence-Based Medicine | 2 | 2018 | 3708 | 0.120 |
Why?
|
Primary Health Care | 1 | 2012 | 4737 | 0.120 |
Why?
|
Nutrition Assessment | 1 | 2018 | 740 | 0.120 |
Why?
|
Catheterization, Peripheral | 1 | 2018 | 346 | 0.120 |
Why?
|
Healthcare Disparities | 2 | 2021 | 3412 | 0.120 |
Why?
|
Natural Language Processing | 1 | 2024 | 1197 | 0.120 |
Why?
|
Vitamin D | 1 | 2008 | 3311 | 0.120 |
Why?
|
Reimbursement Mechanisms | 1 | 2020 | 677 | 0.120 |
Why?
|
Multiple Myeloma | 2 | 2023 | 5192 | 0.120 |
Why?
|
Femoral Artery | 1 | 2018 | 829 | 0.110 |
Why?
|
Bronchi | 1 | 2018 | 847 | 0.110 |
Why?
|
Health Expenditures | 3 | 2023 | 2391 | 0.110 |
Why?
|
Immunotherapy | 2 | 2021 | 4728 | 0.110 |
Why?
|
Ankle Brachial Index | 1 | 2014 | 163 | 0.110 |
Why?
|
Anticonvulsants | 1 | 2023 | 1923 | 0.110 |
Why?
|
Electrocardiography | 2 | 2019 | 6410 | 0.110 |
Why?
|
Respiratory Function Tests | 1 | 2018 | 1697 | 0.110 |
Why?
|
Quality Indicators, Health Care | 2 | 2020 | 1813 | 0.110 |
Why?
|
Cardiovascular Agents | 1 | 2019 | 849 | 0.110 |
Why?
|
Neoplasm Staging | 2 | 2025 | 11249 | 0.110 |
Why?
|
Socioeconomic Factors | 4 | 2022 | 7863 | 0.110 |
Why?
|
Urinary Tract Infections | 1 | 2019 | 806 | 0.100 |
Why?
|
Glucagon-Like Peptide 1 | 3 | 2021 | 367 | 0.100 |
Why?
|
Endothelial Cells | 1 | 2005 | 3586 | 0.100 |
Why?
|
Europe | 1 | 2019 | 3439 | 0.100 |
Why?
|
Colorectal Neoplasms | 3 | 2022 | 6978 | 0.100 |
Why?
|
Stem Cells | 1 | 2005 | 3538 | 0.100 |
Why?
|
Health Surveys | 3 | 2019 | 4056 | 0.100 |
Why?
|
Macular Degeneration | 1 | 2020 | 1016 | 0.100 |
Why?
|
Coronavirus Infections | 2 | 2020 | 3116 | 0.100 |
Why?
|
Anti-Bacterial Agents | 1 | 2011 | 7471 | 0.100 |
Why?
|
Mobility Limitation | 1 | 2016 | 409 | 0.100 |
Why?
|
Follow-Up Studies | 6 | 2021 | 39430 | 0.100 |
Why?
|
Lung Neoplasms | 4 | 2022 | 13589 | 0.100 |
Why?
|
Pneumonia, Viral | 2 | 2020 | 3240 | 0.100 |
Why?
|
Exercise Tolerance | 1 | 2017 | 849 | 0.100 |
Why?
|
Trachea | 1 | 2018 | 1095 | 0.100 |
Why?
|
Malnutrition | 1 | 2018 | 632 | 0.100 |
Why?
|
Neuropsychological Tests | 3 | 2015 | 7134 | 0.100 |
Why?
|
Chronic Disease | 2 | 2024 | 9382 | 0.100 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2021 | 2279 | 0.090 |
Why?
|
Drug Interactions | 1 | 2016 | 1421 | 0.090 |
Why?
|
Feasibility Studies | 1 | 2022 | 5308 | 0.090 |
Why?
|
Antidepressive Agents | 1 | 2023 | 2913 | 0.090 |
Why?
|
Esophageal Neoplasms | 1 | 2021 | 1676 | 0.090 |
Why?
|
Postoperative Period | 2 | 2021 | 1833 | 0.090 |
Why?
|
Placebos | 1 | 2015 | 1668 | 0.090 |
Why?
|
Epidemiologic Research Design | 1 | 2014 | 368 | 0.090 |
Why?
|
Hematologic Neoplasms | 1 | 2022 | 1905 | 0.090 |
Why?
|
Exercise Test | 1 | 2018 | 2186 | 0.090 |
Why?
|
Lower Extremity | 1 | 2018 | 1214 | 0.090 |
Why?
|
Pandemics | 2 | 2020 | 8753 | 0.090 |
Why?
|
Neoplasms | 4 | 2022 | 22386 | 0.080 |
Why?
|
Quality Improvement | 2 | 2022 | 3858 | 0.080 |
Why?
|
Program Evaluation | 1 | 2018 | 2508 | 0.080 |
Why?
|
Pain | 2 | 2023 | 5096 | 0.080 |
Why?
|
Quality Assurance, Health Care | 1 | 2020 | 2179 | 0.080 |
Why?
|
Selection Bias | 1 | 2011 | 360 | 0.080 |
Why?
|
Diagnostic Techniques, Ophthalmological | 1 | 2011 | 252 | 0.080 |
Why?
|
Adaptation, Physiological | 1 | 2016 | 1315 | 0.080 |
Why?
|
Imidazoles | 1 | 2015 | 1174 | 0.080 |
Why?
|
Adult | 10 | 2022 | 223542 | 0.080 |
Why?
|
Patient Preference | 1 | 2016 | 948 | 0.080 |
Why?
|
Sweet Syndrome | 1 | 2009 | 58 | 0.080 |
Why?
|
Heart Diseases | 1 | 2021 | 2816 | 0.080 |
Why?
|
Psychiatric Status Rating Scales | 1 | 2018 | 6035 | 0.080 |
Why?
|
Massachusetts | 1 | 2021 | 8908 | 0.080 |
Why?
|
Interviews as Topic | 1 | 2016 | 2733 | 0.080 |
Why?
|
Pennsylvania | 1 | 2009 | 616 | 0.080 |
Why?
|
Retinol-Binding Proteins, Plasma | 1 | 2008 | 94 | 0.070 |
Why?
|
Urban Population | 1 | 2016 | 2047 | 0.070 |
Why?
|
Neoadjuvant Therapy | 1 | 2019 | 2896 | 0.070 |
Why?
|
Blood Pressure Monitoring, Ambulatory | 1 | 2009 | 252 | 0.070 |
Why?
|
Adverse Drug Reaction Reporting Systems | 1 | 2011 | 495 | 0.070 |
Why?
|
United States Food and Drug Administration | 1 | 2016 | 1669 | 0.070 |
Why?
|
Diastole | 1 | 2009 | 784 | 0.070 |
Why?
|
Abdominal Fat | 1 | 2009 | 221 | 0.070 |
Why?
|
Hospitals, Rural | 1 | 2008 | 176 | 0.070 |
Why?
|
Employment | 1 | 2013 | 1120 | 0.070 |
Why?
|
Leptin | 1 | 2015 | 1598 | 0.070 |
Why?
|
Colonic Neoplasms | 1 | 2018 | 2544 | 0.070 |
Why?
|
Hospitals, Urban | 1 | 2008 | 501 | 0.070 |
Why?
|
Poverty | 1 | 2018 | 2719 | 0.070 |
Why?
|
Injections, Intravenous | 1 | 2009 | 1379 | 0.070 |
Why?
|
Body Composition | 1 | 2016 | 2455 | 0.070 |
Why?
|
Memory | 2 | 2013 | 2210 | 0.070 |
Why?
|
Eating | 1 | 2013 | 1538 | 0.070 |
Why?
|
PPAR gamma | 1 | 2009 | 487 | 0.070 |
Why?
|
Pentoxifylline | 1 | 2006 | 53 | 0.070 |
Why?
|
Sweden | 1 | 2009 | 1382 | 0.060 |
Why?
|
Head and Neck Neoplasms | 1 | 2020 | 2915 | 0.060 |
Why?
|
Gene Expression | 1 | 2018 | 7605 | 0.060 |
Why?
|
Patient Compliance | 1 | 2016 | 2696 | 0.060 |
Why?
|
Aftercare | 2 | 2023 | 921 | 0.060 |
Why?
|
Hematopoietic Stem Cell Mobilization | 1 | 2006 | 225 | 0.060 |
Why?
|
Analgesics, Opioid | 1 | 2021 | 3837 | 0.060 |
Why?
|
Educational Status | 1 | 2012 | 2519 | 0.060 |
Why?
|
Lung | 1 | 2023 | 10090 | 0.060 |
Why?
|
Frontal Lobe | 1 | 2011 | 1427 | 0.060 |
Why?
|
Fatty Acids, Unsaturated | 1 | 2007 | 542 | 0.060 |
Why?
|
Community Health Services | 1 | 2009 | 659 | 0.060 |
Why?
|
Safety | 1 | 2009 | 1159 | 0.060 |
Why?
|
Osteoarthritis, Knee | 1 | 2015 | 1252 | 0.060 |
Why?
|
Blood Glucose | 2 | 2009 | 6429 | 0.060 |
Why?
|
Vasodilation | 1 | 2008 | 968 | 0.060 |
Why?
|
Thiazides | 1 | 2023 | 19 | 0.060 |
Why?
|
Psoas Muscles | 1 | 2024 | 66 | 0.060 |
Why?
|
Body Weight | 1 | 2015 | 4630 | 0.060 |
Why?
|
Sensitivity and Specificity | 1 | 2019 | 14728 | 0.060 |
Why?
|
Granulocyte Colony-Stimulating Factor | 1 | 2006 | 631 | 0.060 |
Why?
|
Intermittent Claudication | 1 | 2006 | 305 | 0.060 |
Why?
|
Amlodipine | 1 | 2023 | 84 | 0.050 |
Why?
|
Antigens, CD34 | 1 | 2005 | 656 | 0.050 |
Why?
|
Women's Health | 1 | 2013 | 2079 | 0.050 |
Why?
|
Smoking | 2 | 2011 | 9099 | 0.050 |
Why?
|
Diabetic Angiopathies | 1 | 2008 | 806 | 0.050 |
Why?
|
Social Class | 2 | 2022 | 2000 | 0.050 |
Why?
|
Body Mass Index | 4 | 2018 | 13030 | 0.050 |
Why?
|
Statistics as Topic | 2 | 2020 | 2362 | 0.050 |
Why?
|
Hypopigmentation | 1 | 2022 | 43 | 0.050 |
Why?
|
Case-Control Studies | 1 | 2020 | 22293 | 0.050 |
Why?
|
Public Health | 2 | 2020 | 2693 | 0.050 |
Why?
|
Sleep Deprivation | 1 | 2009 | 848 | 0.050 |
Why?
|
Dyslipidemias | 1 | 2009 | 874 | 0.050 |
Why?
|
Drug Substitution | 1 | 2024 | 291 | 0.050 |
Why?
|
Pancreatic Neoplasms | 1 | 2019 | 5442 | 0.050 |
Why?
|
Autonomic Nervous System | 1 | 2006 | 709 | 0.050 |
Why?
|
Transportation | 1 | 2022 | 218 | 0.050 |
Why?
|
Drug Therapy, Combination | 1 | 2011 | 6320 | 0.050 |
Why?
|
Multivariate Analysis | 1 | 2014 | 12096 | 0.040 |
Why?
|
Glucose | 2 | 2023 | 4355 | 0.040 |
Why?
|
Dexamethasone | 2 | 2023 | 1965 | 0.040 |
Why?
|
Anti-Arrhythmia Agents | 1 | 2024 | 775 | 0.040 |
Why?
|
Tetrazoles | 1 | 2006 | 922 | 0.040 |
Why?
|
Obesity | 2 | 2015 | 13065 | 0.040 |
Why?
|
Fatty Acids | 1 | 2007 | 1818 | 0.040 |
Why?
|
Melanoma | 1 | 2018 | 5740 | 0.040 |
Why?
|
Homes for the Aged | 1 | 2021 | 273 | 0.040 |
Why?
|
Decision Trees | 1 | 2021 | 510 | 0.040 |
Why?
|
Thymine | 1 | 2019 | 69 | 0.040 |
Why?
|
Adenosine Monophosphate | 1 | 2020 | 233 | 0.040 |
Why?
|
Reproducibility of Results | 1 | 2017 | 20231 | 0.040 |
Why?
|
Skin Neoplasms | 1 | 2018 | 5891 | 0.040 |
Why?
|
Emergency Service, Hospital | 1 | 2018 | 7956 | 0.040 |
Why?
|
Myelodysplastic Syndromes | 1 | 2009 | 1400 | 0.040 |
Why?
|
Wounds and Injuries | 1 | 2011 | 2518 | 0.040 |
Why?
|
Intravitreal Injections | 1 | 2020 | 401 | 0.040 |
Why?
|
Immunization, Passive | 1 | 2020 | 621 | 0.040 |
Why?
|
Home Care Services | 1 | 2024 | 655 | 0.040 |
Why?
|
New York | 1 | 2020 | 882 | 0.040 |
Why?
|
Alanine | 1 | 2020 | 613 | 0.040 |
Why?
|
Lipids | 1 | 2008 | 3346 | 0.040 |
Why?
|
Pyrrolidines | 1 | 2019 | 341 | 0.030 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 1 | 2023 | 1518 | 0.030 |
Why?
|
Absorbable Implants | 1 | 2019 | 339 | 0.030 |
Why?
|
Intensive Care Units | 2 | 2020 | 3805 | 0.030 |
Why?
|
C-Reactive Protein | 1 | 2008 | 3854 | 0.030 |
Why?
|
Environment | 1 | 2022 | 1126 | 0.030 |
Why?
|
Aminopyridines | 1 | 2020 | 578 | 0.030 |
Why?
|
Endothelium, Vascular | 1 | 2008 | 4425 | 0.030 |
Why?
|
Acute Disease | 1 | 2007 | 7246 | 0.030 |
Why?
|
Gastrointestinal Hemorrhage | 1 | 2023 | 1126 | 0.030 |
Why?
|
United States Department of Veterans Affairs | 1 | 2021 | 937 | 0.030 |
Why?
|
Aromatase Inhibitors | 1 | 2020 | 518 | 0.030 |
Why?
|
Factor Analysis, Statistical | 1 | 2018 | 1007 | 0.030 |
Why?
|
Sodium | 1 | 2021 | 1595 | 0.030 |
Why?
|
North America | 1 | 2019 | 1292 | 0.030 |
Why?
|
Erythrocyte Transfusion | 1 | 2020 | 574 | 0.030 |
Why?
|
Benzimidazoles | 1 | 2020 | 864 | 0.030 |
Why?
|
Endpoint Determination | 1 | 2017 | 591 | 0.030 |
Why?
|
Probability | 1 | 2020 | 2483 | 0.030 |
Why?
|
Deoxycytidine | 1 | 2019 | 888 | 0.030 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2009 | 4049 | 0.030 |
Why?
|
Area Under Curve | 1 | 2018 | 1640 | 0.030 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2018 | 876 | 0.030 |
Why?
|
Reoperation | 1 | 2024 | 4342 | 0.030 |
Why?
|
Cross-Over Studies | 1 | 2020 | 2103 | 0.030 |
Why?
|
Estrogens | 1 | 2020 | 1531 | 0.030 |
Why?
|
Multicenter Studies as Topic | 1 | 2018 | 1727 | 0.030 |
Why?
|
Stress, Psychological | 1 | 2008 | 4538 | 0.030 |
Why?
|
Glomerular Filtration Rate | 1 | 2021 | 2226 | 0.030 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2018 | 1104 | 0.030 |
Why?
|
Drug Combinations | 1 | 2019 | 2079 | 0.030 |
Why?
|
Academic Medical Centers | 1 | 2023 | 2785 | 0.020 |
Why?
|
Sirolimus | 1 | 2019 | 1542 | 0.020 |
Why?
|
Polymers | 1 | 2019 | 1631 | 0.020 |
Why?
|
Double-Blind Method | 2 | 2019 | 12450 | 0.020 |
Why?
|
Bone Density | 1 | 2024 | 3561 | 0.020 |
Why?
|
Medication Adherence | 1 | 2022 | 2190 | 0.020 |
Why?
|
Caregivers | 1 | 2023 | 2302 | 0.020 |
Why?
|
Women | 1 | 2012 | 225 | 0.020 |
Why?
|
Postural Balance | 1 | 2015 | 638 | 0.020 |
Why?
|
Angiogenesis Inhibitors | 1 | 2020 | 2062 | 0.020 |
Why?
|
Receptor, erbB-2 | 1 | 2020 | 2586 | 0.020 |
Why?
|
Attention | 1 | 2020 | 2423 | 0.020 |
Why?
|
Korea | 1 | 2009 | 98 | 0.020 |
Why?
|
Insulin | 1 | 2023 | 6606 | 0.020 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2020 | 3520 | 0.020 |
Why?
|
Inpatients | 1 | 2020 | 2561 | 0.020 |
Why?
|
Hypertension, Pulmonary | 1 | 2019 | 1605 | 0.020 |
Why?
|
Prednisolone | 1 | 2009 | 327 | 0.020 |
Why?
|
Young Adult | 3 | 2009 | 60045 | 0.020 |
Why?
|
Critical Illness | 1 | 2020 | 2754 | 0.020 |
Why?
|
Health Personnel | 1 | 2021 | 3384 | 0.020 |
Why?
|
Molecular Targeted Therapy | 1 | 2018 | 2834 | 0.020 |
Why?
|
Magnetic Resonance Imaging | 1 | 2014 | 36840 | 0.020 |
Why?
|
Remission Induction | 1 | 2012 | 2408 | 0.020 |
Why?
|
Antineoplastic Agents | 2 | 2020 | 13708 | 0.020 |
Why?
|
Thiazolidinediones | 1 | 2009 | 462 | 0.020 |
Why?
|
Neoplasm Proteins | 1 | 2018 | 3611 | 0.020 |
Why?
|
Ventricular Function, Left | 1 | 2019 | 3941 | 0.020 |
Why?
|
Regression Analysis | 1 | 2015 | 6353 | 0.020 |
Why?
|
Waist Circumference | 1 | 2009 | 935 | 0.020 |
Why?
|
Carcinoma, Renal Cell | 1 | 2020 | 3197 | 0.020 |
Why?
|
Health Services Accessibility | 1 | 2022 | 5510 | 0.020 |
Why?
|
Delivery of Health Care | 1 | 2023 | 5367 | 0.010 |
Why?
|
Clinical Competence | 1 | 2020 | 4841 | 0.010 |
Why?
|
Kidney Neoplasms | 1 | 2020 | 4298 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2023 | 26395 | 0.010 |
Why?
|
Cell Adhesion Molecules | 1 | 2008 | 1615 | 0.010 |
Why?
|
Protein Kinase Inhibitors | 1 | 2018 | 5709 | 0.010 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2020 | 9425 | 0.010 |
Why?
|
Triglycerides | 1 | 2009 | 2465 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2024 | 20762 | 0.010 |
Why?
|
Treatment Failure | 1 | 2006 | 2656 | 0.010 |
Why?
|
Boston | 1 | 2012 | 9361 | 0.010 |
Why?
|
Glucocorticoids | 1 | 2009 | 2170 | 0.010 |
Why?
|
Ultrasonography | 1 | 2008 | 5995 | 0.010 |
Why?
|
Insulin Resistance | 1 | 2008 | 3974 | 0.010 |
Why?
|
Heart | 1 | 2006 | 4451 | 0.010 |
Why?
|